In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Electrocore (ECOR – Research Report), with a price target of $15.00. The company’s shares opened today at $5.17.
According to TipRanks, Vendetti is an analyst with an average return of -1.1% and a 32.87% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Biolase, ReShape Lifesciences, and Guardion Health Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Electrocore with a $12.50 average price target.
See today’s best-performing stocks on TipRanks >>
ECOR market cap is currently $23.1M and has a P/E ratio of -1.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
Read More on ECOR:
- electroCore reiterates FY23 revenue guidance $14M-$15M, consensus $14.08M
- electroCore sees Q2 revenue $3.55M, consensus $3.28M
- electroCore’s vagus nerve stimulation selected for NFL-funded concussion study
- electroCore announces its TAC-STIM nVNS was selected to be part of AFRL A2PEX
- TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project
